Skip to content

R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances

An Observational, Retrospective, Single-arm, Open US and Israel Study , for Usability Assessment and Algorithm, Development of the Cordio HearO™ Systeam

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05876533
Enrollment
216
Registered
2023-05-25
Start date
2022-03-18
Completion date
2025-03-15
Last updated
2024-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure

Keywords

CHF

Brief summary

To determine the usability and technical aspects of Cordio HearO™

Detailed description

The system (including App and server) will be tested under simulated use conditions with representative users to identify potential changes required to the application user interface, to improve user performance and satisfaction, and to inform future design options. The recordings data will also be used for algorithm improvement

Interventions

DEVICECordio HearO

Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or app) that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients

Sponsors

Cordio Medical
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Major inclusion Criteria: 1. Adults patients 2. Diagnosed with Symptomatic Chronic Heart Failure \[NYHA II-IVa (ambulatory)\] 3. At least one of the following: 1. One ADHF hospitalization in the last 12 months 2. One unplanned IV/SC diuretic administration in the last 6 months 3. Two unplanned IV/SC diuretic administration in the last 12 months 4. NTProBNP \>500 pg/ml or BNP\*\> 150 pg/ml at screening visit 4. Clinically stable HF 5. Willing to participate as evidenced by signing the written informed consent. 6. Male or non-pregnant female patient (pre-menopausal women will confirm verbally). Major

Exclusion criteria

1. Not able to read in Hebrew, Russian, Arabic, English and/or Spanish. 2. Unable to comply with daily use of the App 3. Major cardiovascular event 4. Had a Cardiac Resynchronization Device (CRT) implanted or upgrading ≤ 1 month prior to screening visit. 5. Has estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73 meter square (Cockroft-Gault formula). 6. Is likely to undergo heart transplantation/ LVAD within 6 months of Screening Visit.

Design outcomes

Primary

MeasureTime frameDescription
Patient Usability success defined as: 1.Total and individual usability score of ≥3 in the usability questionnaire in ≥80% of the users.2 yearsThe used scale is: Usability questionnaire for the Cordio HearO™ App. This Usability questionnaire is a subjective evaluation based on Likert score of device user satisfaction. Maximum value for each item: 5 Minimum value for each item: 1 Higher scores means a better outcome
Patient Usability success defined as: 2. Total Compliance2 YearsThe total compliance will be determined by the total number of recording days. Success will be considered if total average compliance of 70 % of all days.

Countries

Israel, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026